Levodopa - Generic Drug Details

What are the generic sources for levodopa and what is the scope of freedom to operate?

Levodopa is the generic ingredient in four branded drugs marketed by Valeant Pharm Intl, Shire, Roche, and Merz, and is included in four NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Levodopa has one hundred and twenty-nine patent family members in twenty-two countries.

There are eighteen drug master file entries for levodopa. One supplier is listed for this compound.

Summary for Levodopa

International Patents:	129
US Patents:	6
Tradenames:	4
Applicants:	4
NDAs:	4
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	134
Clinical Trials:	472
What excipients (inactive ingredients) are in Levodopa?	Levodopa excipients list
DailyMed Link:	Levodopa at DailyMed

Recent Clinical Trials for Levodopa

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Krzysztof Bankiewicz	PHASE1
Hoffmann-La Roche	PHASE3
Prothena Biosciences Limited	PHASE3

See all Levodopa clinical trials

Pharmacology for Levodopa

Drug Class

Aromatic Amino Acid

Medical Subject Heading (MeSH) Categories for Levodopa

Antiparkinson Agents

Dopamine Agents

Anatomical Therapeutic Chemical (ATC) Classes for Levodopa

N04BA	Dopa and dopa derivatives
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for Levodopa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes
Shire	DOPAR	levodopa	TABLET;ORAL	016913-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	LARODOPA	levodopa	CAPSULE;ORAL	016912-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharm Intl	BENDOPA	levodopa	CAPSULE;ORAL	016948-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharm Intl	BENDOPA	levodopa	CAPSULE;ORAL	016948-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for Levodopa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018

EU/EMA Drug Approvals for Levodopa

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Acorda Therapeutics Ireland Limited	Inbrija	levodopa	EMEA/H/C/004786Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.	Authorised	no	no	no	2019-09-19

International Patents for Levodopa

Country	Patent Number	Title	Estimated Expiration
Australia	2013334949
Australia	2018253538
Australia	2020250325
Brazil	112015009088
Canada	2888994

Supplementary Protection Certificates for Levodopa

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	C202330028	Spain		PRODUCT NAME: COMBINACION DE FOSLEVODOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISMA Y FOSCARBIDOPA O UNA SAL FARMACEUTICAMENTE ACEPTABLE DE LA MISM.; NATIONAL AUTHORISATION NUMBER: 88677-SE/H/0415/003/DC; DATE OF AUTHORISATION: 20230220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): 141371; DATE OF FIRST AUTHORISATION IN EEA: 20220825
3209302	11/2023	Austria		PRODUCT NAME: KOMBINATION VON FOSLEVODOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON UND FOSCARBIDOPA ODER EINEM PHARMAZEUTISCH AKZEPTABLEN SALZ DAVON; REGISTRATION NO/DATE: 141371 20220826
3209302	2023C/510	Belgium		PRODUCT NAME: COMBINATIE VAN FOSLEVODOPA EN FOSCARBIDOPA, ELK IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: BE660571 20220901
1613296	92782	Luxembourg		PRODUCT NAME: SAFINAMIDE A UTILISER EN COMBINAISON AVEC LEVODOPA/PDI, ET EVENTUELLEMENT AVEC D'AUTRES MEDICAMENTS PD , POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON; FIRST REGISTRATION DATE: 20150224
3209302	202340008	Slovenia		PRODUCT NAME: COMBINATION OF FOSLEVODOPA OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND FOSCARBIDOPA OR ITS PHARMACEUTICALLY ACCEPTABLE SALT; NATIONAL AUTHORISATION NUMBER: H/05/00514/002; DATE OF NATIONAL AUTHORISATION: 20221215; AUTHORITY FOR NATIONAL AUTHORISATION: SI; FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 141371; DATE OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: 20220825; AUTHORITY OF FIRST AUTHORISATION IN THE EUROPEAN ECONOMIC AREA: AT

Market Dynamics and Financial Trajectory for Levodopa

Last updated: February 20, 2026

Levodopa remains the primary treatment for Parkinson’s disease (PD). Its global market size has grown consistently due to rising PD prevalence, ongoing research, and the development of optimized formulations. The market is projected to expand at a compound annual growth rate (CAGR) of 3-5% over the next five years.

Market Size and Growth Drivers

Current Market Value

In 2022, the global levodopa market was valued at approximately USD 3 billion (Research and Markets, 2022). The growth is driven by an increasing PD population, with estimates suggesting 10 million people globally suffer from PD, expected to double by 2040 (WHO, 2021).

Key Growth Factors

• Aging population: The majority of PD cases occur in patients over 60 years old.
• Improved diagnostics: Earlier detection increases treatment duration.
• New formulations: Extended-release and combined therapies enhance patient compliance and outcomes.
• Healthcare infrastructure in emerging markets: Expanding access raises demand.

Regional Market Distribution

Region	Market Share (2022)	CAGR (2022-2027)
North America	40%	4%
Europe	30%	3.5%
Asia-Pacific	20%	5%
Rest of World	10%	3%

The Asia-Pacific region is expected to experience the fastest CAGR due to expanding healthcare infrastructure and population growth.

Competitive Landscape

Leading Companies

• AbbVie
• Sun Pharmaceutical Industries
• Teva Pharmaceutical Industries
• Boehringer Ingelheim
• AstraZeneca

Market Trends

• Patent expirations for several levodopa formulations hint at increased generic competition.
• Development of new drug combinations and extended-release formulations aims to improve efficacy and reduce side effects.
• Biologics and gene therapy research are still at early stages for Parkinson’s, with levodopa remaining the cornerstone.

Patent Status

Most patent protections for key levodopa formulations expired or are nearing expiration, increasing generic market share. For example, Sinemet (levodopa/carbidopa) patents expired in 2014 in the US, leading to a rise in generic sales.

Pricing and Revenue Projections

Price Trends

• Branded levodopa products average USD 5-10 per tablet.
• Generics are priced around USD 1-3 per tablet.
• Price reductions are anticipated due to increased generic availability.

Revenue Forecasts

Year	Market Revenue (USD Billion)	Growth Rate
2023	3.2	6.7%
2024	3.4	6.1%
2025	3.7	8.8%
2026	4.0	8.1%
2027	4.2	5%

The segment is expected to sustain a steady growth trajectory, primarily driven by demand in Asia-Pacific and innovation in drug delivery methods.

Regulatory Environment and Impact

Approvals and Reimbursement

• Regulatory approvals follow strict safety and efficacy data submissions.
• Reimbursement policies in the US and Europe influence market access and pricing.
• Countries like India have introduced price cap regulations, impacting profit margins.

Impact of Patents

Patent expirations facilitate generic competition, lowering prices but potentially reducing revenues for innovator companies. The launch of biosimilar or alternative formulations could challenge existing market share.

Future Outlook

Opportunities

• Development of levodopa with improved bioavailability.
• New delivery systems (e.g., transdermal patches, infusion pumps).
• Combination therapy with other PD drugs to enhance efficacy.

Risks

• Patent cliffs for key formulations reducing margins.
• Stringent regulatory standards delaying new product launches.
• Market saturation in mature regions.

Key Takeaways

• The global levodopa market will grow annually by approximately 3-5% until 2027.
• Aging populations and rising PD prevalence sustain demand.
• Patent expirations lead to increased generic competition, pressuring prices.
• New formulations and drug delivery innovations present growth avenues.
• Asia-Pacific represents a significant growth opportunity, driven by demographic and infrastructural factors.

FAQs

Q1: How does patent expiry affect levodopa market revenues?
A1: Patent expiry enables generic manufacturers to enter the market, reducing prices and decreasing revenues for branded drugs. However, it can also increase overall market volume due to expanded access.

Q2: What are the main challenges facing the levodopa market?
A2: Patent expirations, pricing pressures, regulatory hurdles, and competition from emerging therapies pose challenges.

Q3: Which regions offer the most growth potential?
A3: The Asia-Pacific region presents the highest growth potential due to demographic trends, healthcare expansion, and lower market saturation.

Q4: What are the emerging trends in levodopa formulations?
A4: Extended-release formulations, combination products, and delivery systems like transdermal patches are gaining attention for improving patient adherence.

Q5: How does the aging global population influence levodopa demand?
A5: It increases PD cases, thereby fueling demand for levodopa, the primary treatment for PD motor symptoms.

---

References

1. Research and Markets. (2022). Levodopa Market Size, Share & Trends Analysis Report.
2. World Health Organization. (2021). Global Parkinson’s Disease Statistics.